COVID vaccine developer BioNTech sees profits rise
German pharmaceutical company BioNTech says its earnings grew again in the third quarter
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.German pharmaceutical company BioNTech which partnered with Pfizer to develop the first widely used COVID-19 vaccine, said Tuesday that its earnings grew again in the third quarter.
BioNTech, which is based in Mainz reported a net profit of more than 3.2 billion euros ($3.7 billion) for the July-September period. That compares with the company's loss of 210 million euros ($243 million) in the same period a year earlier and a second-quarter profit of almost 2.8 billion euros ($3.2 billion). Vaccinations with the Pfizer-BioNTech vaccine started started in December.
BioNTech reported revenue of nearly 6.1 billion euros ($7.1 billion), up from 67.5 million euros ($78 million) in the third quarter of 2020. It said that more than 2 billion doses of the COVID-19 vaccine, marketed as Comirnaty, had been delivered this year as of Nov. 2.
Based on an expected total of up to 2.5 billion doses, BioNTech said it predicts revenue from the coronavirus vaccine for the full year to add up to 16 to 17 billion euros ($18.5 billion to $19.7 billion).
The company has said the windfall from its mRNA-based coronavirus vaccine will help it to develop drugs against cancer and other diseases.
BioNTech's net profit for the year's first nine months was over 7.1 billion euros ($8.2 billion), compared with a loss of 351.7 million euros ($407 million) in the same period a year earlier.
___
Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.